Ontology highlight
ABSTRACT:
SUBMITTER: Wilkin TJ
PROVIDER: S-EPMC2917795 | biostudies-literature | 2010 Aug
REPOSITORIES: biostudies-literature
Wilkin Timothy J TJ Su Zhaohui Z Krambrink Amy A Long Jianmin J Greaves Wayne W Gross Robert R Hughes Michael D MD Flexner Charles C Skolnik Paul R PR Coakley Eoin E Godfrey Catherine C Hirsch Martin M Kuritzkes Daniel R DR Gulick Roy M RM
Journal of acquired immune deficiency syndromes (1999) 20100801 5
<h4>Background</h4>Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity.<h4>Methods</h4>Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. Vicriviroc (5, 10, or 15 mg) or placebo was added to a failing regimen with optimization of background antiretroviral medications at day 14. Subjects experiencing virologic failure and subjects completing 48 weeks were offered open-label vicriviro ...[more]